A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 2/3 Recruiting
660 enrolled
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1 Recruiting
140 enrolled
MajesTEC-7
Phase 3 Recruiting
1,590 enrolled
DURGA-4
Phase 3 Recruiting
508 enrolled
Iber-KDd
Phase 2 Recruiting
30 enrolled
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Phase NA Recruiting
41 enrolled
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Phase 2 Recruiting
20 enrolled
MagnetisMM-6
Phase 3 Recruiting
1,116 enrolled
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 Recruiting
288 enrolled
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 Recruiting
1,450 enrolled
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Phase 2 Recruiting
20 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled